Reversal of myeloid cell - mediated immunosuppression in patients with metastatic renal cell carcinoma

Sergei Kusmartsev, Zhen Su, Axel Heiser, Jens Dannull, Evgeniy Eruslanov, Hubert Kübler, Donna Yancey, Philip Dahm, Johannes Vieweg

Research output: Contribution to journalArticlepeer-review

239 Scopus citations

Abstract

Purpose: Tumor-induced immunosuppression remains a significant obstacle that limits the efficacy of biological therapy for renal cell carcinoma. Here we evaluate the role of CD33 myeloid-derived suppressor cells (MDSC) in the regulation of T-cell responses in renal cell carcinoma patients. We also examine effect of a//-trans-retinoic acid (ATRA) on MDSC-mediated immune suppression. Experimental Design: CD33-positive myeloid cells were isolated from the peripheral blood of renal cell carcinoma patients with magnetic beads and tested in vitro for their ability to inhibit T-cell responses. T-cell function was evaluated using ELISPOTand CTL assays. Results: MDSC isolated from renal cell carcinoma patients, but not from healthy donors, were capable of suppressing antigen-specificT-cell responses in vitro through the secretion of reactive oxygen species and nitric oxide upon interaction with CTL. MDSC-mediated immune suppression and IFN-γ down-regulation was reversible in vitro by exposing cells to the reactive oxygen species inhibitors. Moreover, ATRA was capable of abrogating MDSC-mediated immunosuppression and improvingT-cell function by direct differentiation into antigen-presenting cell precursors. Conclusions: These results may have significant implications regarding the future design of active immunotherapy protocols that may include differentiation agents as part of a multimodal approach to renal cell carcinoma immunotherapy.

Original languageEnglish (US)
Pages (from-to)8270-8278
Number of pages9
JournalClinical Cancer Research
Volume14
Issue number24
DOIs
StatePublished - Dec 15 2008

Fingerprint Dive into the research topics of 'Reversal of myeloid cell - mediated immunosuppression in patients with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this